← Back to Clinical Trials
Recruiting NCT04661215

NCT04661215 Pyloric Sphincter Abnormalities in Patients With Gastroparesis Symptoms

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04661215
Status Recruiting
Phase
Sponsor Johns Hopkins Bloomberg School of Public Health
Condition Gastroparesis
Study Type OBSERVATIONAL
Enrollment 150 participants
Start Date 2026-01-13
Primary Completion 2027-03-30

Trial Parameters

Condition Gastroparesis
Sponsor Johns Hopkins Bloomberg School of Public Health
Study Type OBSERVATIONAL
Phase N/A
Enrollment 150
Sex ALL
Min Age 18 Years
Max Age 85 Years
Start Date 2026-01-13
Completion 2027-03-30

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The overall objective of this study is to determine if there are pyloric sphincter abnormalities in patients with gastroparesis symptoms and determine how prevalent these abnormalities are using tests to assess the pyloric sphincter - endoluminal functional luminal imaging probe (Endoflip™), water load satiety testing (WLST), and high-resolution cutaneous electrogastrography (HR-EGG) using Gastric Alimetry™ System.

Eligibility Criteria

Inclusion Criteria FOR SYMPTOMATIC PARTICIPANTS: 1. Provision of signed and dated informed consent form. 2. Stated willingness to comply with all study procedures and availability for the duration of the study. 3. Male or female, aged 18-85 4. Symptoms of gastroparesis, either diabetic or idiopathic etiology 5. Symptoms of gastroparesis with minimum Gastroparesis Cardinal Symptom Index (GCSI) score of 2.0 6. Individual will have had a prior 4-hour gastric emptying scintigraphy test performed for clinical evaluation within the last 6 months. This gastric emptying test would be done for clinical evaluation and is not part of the research study. From these participants with gastroparesis symptoms, we will include those with delayed gastric emptying as well as those with normal gastric emptying. 7. Participant must not initiate any new treatments until completion of the study procedures. 8. Willingness to: 1. Stop histamine 2 antagonists, prokinetics (e.g., metoclopramide, erythromycin, do

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology